Puma Biotechnology vs Stoke Therapeutics
Puma Biotechnology reported revenue of $228 million in fiscal 2025, 1.2 times Stoke Therapeutics' $184 million in fiscal 2025. Puma Biotechnology's revenue fell 0.9% in its latest year, and Stoke Therapeutics' grew 404.5%. Puma Biotechnology had an operating margin of 16.3%, against -11.2% at Stoke Therapeutics. Free cash flow was $42 million at Puma Biotechnology and $45 million at Stoke Therapeutics.
Side by side
| Puma Biotechnology | Stoke Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $228M | $184M |
| Revenue growth | −0.9% | 404.5% |
| Revenue growth a year, last 5 years | 0.3% | — |
| Gross margin | 74.5% | — |
| Operating margin | 16.3% | −11.2% |
| Net margin | 13.6% | −3.7% |
| Free cash flow | $42M | $45M |
| Free cash flow margin | 18.3% | 24.4% |
| Return on capital | 48.2% | — |
| Net debt to EBITDA | −1.4x | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 3.2% | 9.7% |
| Last close | $7.77 | $26.68 |
| P/E at the last close | 16.9× | — |
| Insider trades, last 12 months | — | sold $8.7 million |
| Piotroski F-score | 8 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Puma BiotechnologyStoke Therapeutics
Operating margin
Percent of revenue
Puma BiotechnologyStoke Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Puma BiotechnologyStoke Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Puma Biotechnology and Stoke Therapeutics pages.